Continue Reading
Full article on Unknown
HSBC Turns More Bullish on Amgen (AMGN) into 2026
Market Intelligence Analysis
AI-Powered
Why This Matters
HSBC has upgraded its price target for Amgen Inc. (AMGN) to $425 from $381, maintaining a Buy rating as part of its positive outlook for the pharmaceutical sector through 2026. This indicates a strong belief in Amgen's future performance and potential growth.
Market Impact
Market impact analysis based on bullish sentiment with 82% confidence.
Sentiment
Bullish
AI Confidence
82%
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dogs of the Dow to Invest in. On December 8, HSBC lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $425 from $381. The firm also retained a Buy rating. The call came as part of the firm’s 2026 outlook for the pharma sector. HSBC sees […]
Original article published by
Unknown
on December 17, 2025.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.